News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Conference Call Today at 4:30pm ET
View HTML
Toggle Summary Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014
SHELTON, Conn., March 20, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will
View HTML
Toggle Summary Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
SHELTON, Conn., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the closing of its initial
View HTML
Toggle Summary Cara Therapeutics Announces Pricing of Initial Public Offering
SHELTON, Conn., Jan. 31, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the pricing of its initial public
View HTML
Toggle Summary Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
SHELTON, Conn., Nov. 11, 2013 /PRNewswire/ -- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that it has filed a registration statement
View HTML
Toggle Summary Cara Therapeutics Reports Positive Results from Phase 2 Clinical Trial I.V. CR845, for Post-Operative Pain Following Bunionectomy
Cara Therapeutics Reports Positive Results from Phase 2 Clinical Trial I.V. CR845, for Post-Operative Pain Following Bunionectomy SHELTON, Conn., Oct. 29, 2013 /PRNewswire -- Cara Therapeutics, Inc. today announced top-line results from a Phase 2 clinical trial of its novel, peripherally-acting
View HTML
Toggle Summary Cara Therapeutics to Present at Stifel 2013 Healthcare Conference
SHELTON, Conn., September 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Stifel 2013 Healthcare Conference on Wednesday, September 11, 2013 at 11:30 a.m. ET in Boston.
View HTML
Toggle Summary Cara Therapeutics to Present at 2013 Wedbush Securities Life Sciences Management Access Conference
SHELTON, Conn., August 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, August 14, 2013 at 12:45 p.m. ET in New York City.
View HTML
Toggle Summary Cara Therapeutics Enters Into Development and Commercial Alliance with Maruishi for Novel Kappa Opioid Agonist, CR845, in Japan
Focus on Acute Pain and Uremic Pruritus
View HTML
Toggle Summary Cara Therapeutics Reports Positive Results from Phase II Trial of Novel Peripheral Kappa Agonist, CR845, in Acute Post-Operative Pain
- Statistically significant decreases in morphine use and pain intensity demonstrated in 24-hour period after surgery with pre- and post-operative administration of CR845 -
View HTML